Head-To-Head Analysis: Audentes Therapeutics (BOLD) vs. Biogen (BIIB)

Audentes Therapeutics (NASDAQ: BOLD) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings for Audentes Therapeutics and Biogen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Audentes Therapeutics 0 2 8 0 2.80
Biogen 0 9 20 0 2.69

Audentes Therapeutics presently has a consensus target price of $35.38, indicating a potential downside of 9.64%. Biogen has a consensus target price of $367.22, indicating a potential upside of 37.43%. Given Biogen’s higher probable upside, analysts clearly believe Biogen is more favorable than Audentes Therapeutics.

Volatility and Risk

Audentes Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Audentes Therapeutics and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics N/A N/A -52.37%
Biogen 20.69% 38.32% 20.72%

Earnings & Valuation

This table compares Audentes Therapeutics and Biogen’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics N/A N/A -$90.23 million ($3.40) -11.51
Biogen $12.27 billion 4.61 $2.54 billion $21.81 12.25

Biogen has higher revenue and earnings than Audentes Therapeutics. Audentes Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.0% of Audentes Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Biogen shares are held by institutional investors. 47.3% of Audentes Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Biogen beats Audentes Therapeutics on 10 of the 13 factors compared between the two stocks.

About Audentes Therapeutics

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply